听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览HIV CLINICAL TRIALS期刊下所有文献
  • Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

    abstract:METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/0B0R-J1LP-KQPF-43HB

    authors: Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

    更新日期:2006-01-01 00:00:00

  • Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

    abstract:BACKGROUND:To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD:HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/A686-M37Y-J2PT-E9GJ

    authors: Lowe SH,Wensing AM,Hassink EA,ten Kate RW,Richter C,Schreij G,Koopmans PP,Juttmann JR,van der Tweel I,Lange JM,Borleffs JC

    更新日期:2005-09-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract:PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HAG3-8YA5-UDQC-36NX

    authors: Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期:2005-03-01 00:00:00

  • The 2004 International AIDS Conference and how to globally counter HIV/AIDS.

    abstract::This article reports noteworthy HIV/AIDS clinical trials presented at the XVth International AIDS Conference, Bangkok, July 2004, and also outlines goals of comprehensive prevention, care, treatment, and monitoring plans. The Bangkok conference theme was "Access for All." Outlined are goals of comprehensive prevention...

    journal_title:HIV clinical trials

    pub_type:

    doi:10.1310/RM35-RE2A-J9L2-8J47

    authors: Idemyor V

    更新日期:2005-01-01 00:00:00

  • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

    abstract:PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/RRX7-49ME-27V7-MWWV

    authors: MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

    更新日期:2004-11-01 00:00:00

  • Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

    abstract:PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/WT81-MEM4-5C4L-CHPK

    authors: Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

    更新日期:2004-09-01 00:00:00

  • Update on HIV lipodystrophy.

    abstract::When prescribed appropriately and taken adherently, antiretroviral therapy can consistently and durably suppress HIV replication, potentially translating into years of near normal health for HIV-infected persons. However, presently available antiretrovirals are associated with a cluster of physical and metabolic sympt...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/XP75-7VJ5-HML2-YF1W

    authors: Kravcik S

    更新日期:2004-05-01 00:00:00

  • Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes.

    abstract:BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/X618-KWKJ-WCTQ-LQ2L

    authors: Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

    更新日期:2003-11-01 00:00:00

  • Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

    abstract:PURPOSE:The objectives of this study were to determine the prevalence of osteopenia and the factors associated with its presence in HIV-infected patients under highly active antiretroviral therapy (HAART) and to assess the changes of bone mineral density (BMD) in a population followed prospectively. METHOD:BMD was ass...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/4X0H-UVMJ-BHYW-CPFB

    authors: Fernández-Rivera J,García R,Lozano F,Macías J,García-García JA,Mira JA,Corzo JE,Gómez-Mateos J,Rueda A,Sánchez-Burson J,Pineda JA

    更新日期:2003-09-01 00:00:00

  • Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study.

    abstract:BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究

    doi:10.1310/4nb4-1gx6-4xvk-pbgl

    authors: Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

    更新日期:2003-07-01 00:00:00

  • Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study.

    abstract:PURPOSE:The objective was to evaluate the impact of an intervention for improving adherence to antiretroviral therapies (HAART) in HIV-infected patients. METHOD:We designed a prospective, controlled, randomized trial to assess the impact of an educational and counseling intervention in addition to standard of care. At...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/brbv-3941-h1pp-ndry

    authors: Pradier C,Bentz L,Spire B,Tourette-Turgis C,Morin M,Souville M,Rebillon M,Fuzibet JG,Pesce A,Dellamonica P,Moatti JP

    更新日期:2003-03-01 00:00:00

  • HIV production from purified monocytes isolated from antiretroviral-naïve and protease inhibitor-treated HIV-1-infected patients.

    abstract:PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/EF26-V3PC-AG5X-FCF4

    authors: Kazanjian P,Adams D,Tate S,Newman G

    更新日期:2002-11-01 00:00:00

  • Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

    abstract::Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/7bwp-0x7f-nxna-qrnp

    authors: Holguín A,Soriano V

    更新日期:2002-09-01 00:00:00

  • Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV.

    abstract:OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/N34A-653T-ABF5-8Q1R

    authors: Levett PN,Hirschman SZ,Roach TC,Broome H,Alexander RJ,Fraser HS

    更新日期:2002-07-01 00:00:00

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

    abstract:BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HP8B-NF27-VFWA-80YX

    authors: Bernstein ZP,Brooks SP,Chanan-Khan A,Gollnick SO,Gilbert MJ,Miller KC,Tomasi TB

    更新日期:2002-05-01 00:00:00

  • Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

    abstract:OBJECTIVE:To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily. DESIGN:Prospective, single-center study. METHOD:The patient database of the department of infectious diseases was screened for patients who had failed at lea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/RFT5-7N0M-8C5G-0TL2

    authors: Arvieux C,Tattevin P,Souala FM,Jaccard P,Ruffault A,Bentué-Ferrer D,Tribut O,Chapplain JM,Dupont M,Bouvier C,Michelet C

    更新日期:2002-03-01 00:00:00

  • Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

    abstract:BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1310/FAJF-7A8G-QAR4-Q0X5

    authors: de Mendoza C,Ramos JT,Ciria L,Fortuny C,García FJ,de José MI,Asensi F,Soriano V

    更新日期:2002-01-01 00:00:00

  • Tuberculosis and HIV infection: epidemiology, immunology, and treatment.

    abstract::Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/TUNH-UAKU-N0E4-1PXF

    authors: Schluger NW,Burzynski J

    更新日期:2001-07-01 00:00:00

  • Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.

    abstract:PURPOSE:This retrospective study investigates the effect of prior nucleoside (nucleoside reverse transcriptase inhibitor [NRTI]) experience on 2-year virologic response to an initial protease inhibitor-highly active antiretroviral therapy (PI-HAART) regimen. METHOD:152 patients who started a PI (excluding saquinavir h...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/W17C-5DBH-D90E-17CG

    authors: Kazanjian P,Tashima K,Hollander T,Kaul D

    更新日期:2001-05-01 00:00:00

  • The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

    abstract:PURPOSE:To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). METHOD:A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/KED4-8TW3-4ARG-HFC5

    authors: Jensen-Fangel S,Kirk O,Blaxhult A,Gerstoft J,Pedersen C,Black FT,Lundgren JD,Obel N

    更新日期:2001-03-01 00:00:00

  • Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?

    abstract:PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/2V0B-HDWC-AGWR-H56M

    authors: Corales RB,Shrestha NK,Taege AJ,Isada CM,Rehm SJ,Schmitt SK,Gordon SM,Mawhorter SD

    更新日期:2001-01-01 00:00:00

  • Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.

    abstract:PURPOSE:Previous studies with intermittent interleukin-2 (IL-2) therapy using intermediate and high levels of IL-2 have demonstrated significant increases in the CD4 + T cell count in HIV-infected patients. Intermittent regimens are amenable to outpatient use, but severe adverse events are frequently experienced with i...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1310/T5FR-8JPX-0NEF-XDKD

    authors: Lalezari JP,Beal JA,Ruane PJ,Cohen CJ,Jacobson EL,Sundin D,Leong WP,Raffanti SP,Wheeler DA,Anderson RD,Keiser P,Schrader SR,Goodgame JC,Steinhart CR,Murphy RL,Wolin MJ,Smith KA

    更新日期:2000-11-01 00:00:00

62 条记录 2/2 页 « 12 »